Fulcrum Therapeutics (FULC) Current Leases (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Current Leases data on file, last reported at $2.5 million in Q1 2026.

• On a quarterly basis, Current Leases rose 9.92% year-over-year to $2.5 million in Q1 2026; TTM through Mar 2026 was $2.5 million, a 9.92% increase from a year earlier, with the FY2025 full-year figure at $2.4 million, up 9.97% from the prior year.
• Current Leases for Q1 2026 stood at $2.5 million, up from $2.4 million in the prior quarter.
• Over the last five years, Current Leases for FULC reached as high as $2.7 million in Q1 2023 and fell as low as $2.0 million in Q1 2024.
• Historically, Current Leases has averaged $2.3 million across 5 years, with a median of $2.4 million in 2023.
• Across the five-year window, Current Leases surged 60550.0% in 2022 and declined 23.7% in 2024, its largest moves.
• Year by year, Current Leases stood at $2.6 million in 2022, then retreated by 15.76% to $2.2 million in 2023, then decreased by 0.27% to $2.2 million in 2024, then advanced by 9.97% to $2.4 million in 2025, then advanced by 2.37% to $2.5 million in 2026.
• Per Business Quant data, the three most recent Current Leases figures were $2.5 million in Q1 2026, $2.4 million in Q4 2025, and $2.3 million in Q3 2025.